Journal Article

Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema

Bobrow, Dylan, Geraghty, Patrick, Costanzo, Louis, Taluru, Harsha, Mueller, Christian, Ohlmeyer, Michael, Park, Sangmi S., Yu, Howard, Pillai, Meshach, Reece, Joshua, Jundi, Bakr, Ploszaj, Magdalena, Ahmed, Huma, Foronjy, Robert F., Lafortune, Pascale, Dabo, Abdoulaye J., Soto, Brian

2023

Overview

Abstract The activity of PP2A (protein phosphatase 2A), a serine-threonine phosphatase, is reduced by chronic cigarette smoke (SM) exposure and α-1 antitrypsin (AAT) deficiency, and chemical activation of PP2A reduces the loss of lung function in SM-exposed mice. However, the previously studied PP2A-activator tricyclic sulfonamide compound DBK-1154 has low stability to oxidative metabolism, resulting in fast clearance and low systemic exposure. Here we compare the utility of a new more stable PP2A activator, ATUX-792, versus DBK-1154 for the treatment of SM-induced emphysema. ATUX-792 was also tested in human bronchial epithelial cells and a mouse model of AAT deficiency, Serpina1a-e–knockout mice. Human bronchial epithelial cells were treated with ATUX-792 or DBK-1154, and cell viability, PP2A activity, and MAP (mitogen-activated protein) kinase phosphorylation status were examined. Wild-type mice received vehicle, DBK-1154, or ATUX-792 orally in the last 2 months of 4 months of SM exposure, and 8-month-old Serpina1a-e–knockout mice received ATUX-792 daily for 4 months. Forced oscillation and expiratory measurements and histology analysis were performed. Treatment with ATUX-792 or DBK-1154 resulted in PP2A activation, reduced MAP kinase phosphorylation, immune cell infiltration, reduced airspace enlargements, and preserved lung function. Using protein arrays and multiplex assays, PP2A activation was observed to reduce AAT-deficient and SM-induced release of CXCL5, CCL17, and CXCL16 into the airways, which coincided with reduced neutrophil lung infiltration. Our study indicates that suppression of the PP2A activity in two models of emphysema could be restored by next-generation PP2A activators to impact lung function.

• Publisher: Oxford University Press,American Thoracic Society
• Subject: Animals / Cigarette smoke / Emphysema / Emphysema - drug therapy / Emphysema - metabolism / Epithelial cells / Humans / Infant / Infiltration / Leukocytes (neutrophilic) / Lung - metabolism / Lung cancer / Lung diseases / MAP kinase / Mice / Mice, Knockout / Original Research / Phosphoprotein phosphatase / Phosphorylation / Protein phosphatase / Protein Phosphatase 2 - metabolism / Protein-serine/threonine phosphatase / Proteins / Pulmonary Emphysema - drug therapy / Pulmonary Emphysema - metabolism / Respiratory function / Rodents / Threonine phosphatase